Literature DB >> 23918244

Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users.

H Reddon1, M-J Milloy, A Simo, J Montaner, E Wood, T Kerr.   

Abstract

We sought to examine whether methadone maintenance therapy (MMT) decreased rates of antiretroviral therapy (ART) discontinuation and was associated with plasma HIV RNA responses among a cohort of illicit drug users. Cumulative ART discontinuation rates were estimated using Kaplan-Meier methods and factors independently associated with ART discontinuation were identified using Cox proportional hazards regression. Engagement in MMT was negatively and independently associated with ART discontinuation [Adjusted Relative Hazard = 0.67 (95 % CI 0.54-0.83); p < 0.001]. Among participants receiving ART and MMT, 81.6 % of plasma HIV-1 RNA assessments were <500 copies/mL, while 65.81 % of HIV-1 RNA assessments among those prescribed ART without MMT were <500 copies/mL (p < 0.001). These results demonstrate that engagement in MMT conferred a protective benefit against ART discontinuation and was associated with a significant increase in plasma HIV RNA suppression among HIV-infected opioid-dependent drug users.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23918244      PMCID: PMC4059183          DOI: 10.1007/s10461-013-0584-z

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  45 in total

1.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Patient-perceived barriers to antiretroviral adherence: associations with race.

Authors:  T F Ferguson; K E Stewart; E Funkhouser; J Tolson; A O Westfall; M S Saag
Journal:  AIDS Care       Date:  2002-10

3.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

4.  Psychiatric issues in the management of patients with HIV infection.

Authors:  G J Treisman; A F Angelino; H E Hutton
Journal:  JAMA       Date:  2001-12-12       Impact factor: 56.272

5.  Trust and the acceptance of and adherence to antiretroviral therapy.

Authors:  F L Altice; F Mostashari; G H Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2001-09-01       Impact factor: 3.731

6.  Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.

Authors:  Robert S Hogg; Katherine Heath; David Bangsberg; Benita Yip; Natasha Press; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

Review 7.  Using HIV viral load to guide treatment-for-prevention interventions.

Authors:  Vladimir Novitsky; Max Essex
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

8.  Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Authors:  Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

9.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

10.  Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.

Authors:  Evan Wood; Julio S G Montaner; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  J Infect Dis       Date:  2003-10-01       Impact factor: 5.226

View more
  26 in total

Review 1.  HIV treatment cascade in MSM, people who inject drugs, and sex workers.

Authors:  Kathryn Risher; Kenneth H Mayer; Chris Beyrer
Journal:  Curr Opin HIV AIDS       Date:  2015-11       Impact factor: 4.283

2.  Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention.

Authors:  Mina Psichogiou; George Giallouros; Katerina Pantavou; Eirini Pavlitina; Martha Papadopoulou; Leslie D Williams; Andria Hadjikou; Eleni Kakalou; Athanasios Skoutelis; Konstantinos Protopapas; Anastasia Antoniadou; George Boulmetis; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; Georgios K Nikolopoulos
Journal:  AIDS Care       Date:  2019-04-02

3.  Oral Fluid vs. Urine Analysis to Monitor Synthetic Cannabinoids and Classic Drugs Recent Exposure.

Authors:  Vincent Blandino; Jillian Wetzel; Jiyoung Kim; Petrit Haxhi; Richard Curtis; Marta Concheiro
Journal:  Curr Pharm Biotechnol       Date:  2017       Impact factor: 2.837

4.  'PrEP is not ready for our community, and our community is not ready for PrEP': pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response.

Authors:  Andy Guise; Eliot Ross Albers; Steffanie A Strathdee
Journal:  Addiction       Date:  2016-06-08       Impact factor: 6.526

5.  Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: An observational cohort study.

Authors:  Yan Zhao; Mingjie Zhang; Cynthia X Shi; Jie Huang; Fujie Zhang; Keming Rou; Zunyou Wu
Journal:  Drug Alcohol Depend       Date:  2016-11-19       Impact factor: 4.492

Review 6.  Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences.

Authors:  Andy Guise; Maureen Seguin; Gitau Mburu; Susie McLean; Pippa Grenfell; Zahed Islam; Sergii Filippovych; Happy Assan; Andrea Low; Peter Vickerman; Tim Rhodes
Journal:  AIDS Care       Date:  2017-03-10

7.  Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

Authors:  Leslie Lappalainen; Seonaid Nolan; Sabina Dobrer; Cathy Puscas; Julio Montaner; Keith Ahamad; Huiru Dong; Thomas Kerr; Evan Wood; M-J Milloy
Journal:  Addiction       Date:  2015-08       Impact factor: 6.526

8.  Dispensation of antiretroviral therapy and methadone maintenance therapy at the same facility in a low-barrier setting linked to optimal adherence to HIV treatment.

Authors:  N A Mohd Salleh; N Fairbairn; S Nolan; R Barrios; J Shoveller; L Richardson; M-J Milloy
Journal:  HIV Med       Date:  2019-07-29       Impact factor: 3.180

9.  Gender differences in access to methadone maintenance therapy in a Canadian setting.

Authors:  Paxton Bach; M-J Milloy; Paul Nguyen; John Koehn; Silvia Guillemi; Thomas Kerr; Evan Wood
Journal:  Drug Alcohol Rev       Date:  2015-03-04

10.  Client Acceptability for Integrating Antiretroviral Therapy in Methadone Maintenance Therapy Clinics in Sichuan, China.

Authors:  Chunqing Lin; Li Li; Xiaobin Cao
Journal:  Subst Use Misuse       Date:  2016-09-28       Impact factor: 2.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.